Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.

Detalles Bibliográficos
Autores principales: Gendron, Nicolas, Feral‐Pierssens, Anne Laure, Jurcisin, Igor, de Raucourt, Emmanuelle, Bouton, Valerie, Fischer, Anne Marie, Lorenceau‐Savale, Camille, Lillo‐Le Louët, Agnès, Smadja, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331231/
https://www.ncbi.nlm.nih.gov/pubmed/28265404
http://dx.doi.org/10.1002/ccr3.839
_version_ 1782511332834148352
author Gendron, Nicolas
Feral‐Pierssens, Anne Laure
Jurcisin, Igor
de Raucourt, Emmanuelle
Bouton, Valerie
Fischer, Anne Marie
Lorenceau‐Savale, Camille
Lillo‐Le Louët, Agnès
Smadja, David M.
author_facet Gendron, Nicolas
Feral‐Pierssens, Anne Laure
Jurcisin, Igor
de Raucourt, Emmanuelle
Bouton, Valerie
Fischer, Anne Marie
Lorenceau‐Savale, Camille
Lillo‐Le Louët, Agnès
Smadja, David M.
author_sort Gendron, Nicolas
collection PubMed
description Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.
format Online
Article
Text
id pubmed-5331231
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53312312017-03-06 Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding Gendron, Nicolas Feral‐Pierssens, Anne Laure Jurcisin, Igor de Raucourt, Emmanuelle Bouton, Valerie Fischer, Anne Marie Lorenceau‐Savale, Camille Lillo‐Le Louët, Agnès Smadja, David M. Clin Case Rep Case Reports Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy. John Wiley and Sons Inc. 2017-02-10 /pmc/articles/PMC5331231/ /pubmed/28265404 http://dx.doi.org/10.1002/ccr3.839 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Gendron, Nicolas
Feral‐Pierssens, Anne Laure
Jurcisin, Igor
de Raucourt, Emmanuelle
Bouton, Valerie
Fischer, Anne Marie
Lorenceau‐Savale, Camille
Lillo‐Le Louët, Agnès
Smadja, David M.
Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
title Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
title_full Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
title_fullStr Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
title_full_unstemmed Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
title_short Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
title_sort real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331231/
https://www.ncbi.nlm.nih.gov/pubmed/28265404
http://dx.doi.org/10.1002/ccr3.839
work_keys_str_mv AT gendronnicolas realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding
AT feralpierssensannelaure realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding
AT jurcisinigor realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding
AT deraucourtemmanuelle realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding
AT boutonvalerie realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding
AT fischerannemarie realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding
AT lorenceausavalecamille realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding
AT lillolelouetagnes realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding
AT smadjadavidm realworlduseofidarucizumabfordabigatranreversalinthreecasesofseriousbleeding

Ejemplares similares